MannKind Announces Afrezza® Distribution Agreement in Australia
May 16 2019 - 4:01PM
MannKind Corporation (Nasdaq: MNKD) today
announced that it has entered into an exclusive marketing and
distribution agreement with the AMSL Diabetes division of
Australasian Medical & Scientific Ltd. for the
commercialization of Afrezza® (insulin human) Inhalation Powder in
Australia.
"We are excited to partner with AMSL Diabetes to
accelerate patients’ access to Afrezza in Australia," said Michael
Castagna, Chief Executive Officer of MannKind Corporation. “This
agreement with AMSL, our third international partnership for
Afrezza, aligns us with a partner with a strong presence and
knowledge of the diabetes market in Australia, giving us an
opportunity to provide more healthcare providers and patients with
a new option in their fight against diabetes."
“Adding Afrezza to our portfolio is a
significant step towards addressing the needs of Australian
patients with diabetes who are looking for a mealtime insulin with
a unique time-action profile,” said Richard Plowright, Managing
Director of AMSL. “Through our exclusive partnership with MannKind,
we can bring the benefits of inhalable insulin to patients across
Australia.”
Under the terms of the agreement, AMSL Diabetes
will be responsible for obtaining regulatory and reimbursement
approvals to distribute Afrezza in Australia. AMSL Diabetes will
also be responsible for sales, marketing, and customer support and
distribution activities. MannKind will retain responsibility for
supply and manufacturing of Afrezza.
About Afrezza®Available by
prescription, Afrezza® (insulin human) Inhalation Powder is a
rapid-acting inhaled insulin indicated to improve glycemic control
in adult patients with diabetes mellitus. Afrezza consists of a dry
powder formulation of human insulin delivered from a small and
portable inhaler. Administered at the beginning of a meal, Afrezza
dissolves rapidly upon inhalation to the lung and passes quickly
into the bloodstream (in less than one minute). This rapid
absorption allows Afrezza to begin reducing blood sugar levels
within about 12 minutes of administration. Afrezza is available in
4-unit, 8-unit and 12-unit single-dose cartridges of insulin powder
that can be used, as prescribed by a health care professional, in
combination with other diabetes medications to achieve target blood
sugar levels. For Afrezza doses exceeding 12 units, patients may
use a combination of existing cartridge strengths. For more
information on Afrezza, please visit www.afrezza.com.
About MannKind
CorporationMannKind Corporation (NASDAQ:MNKD) focuses
on the development and commercialization of inhaled therapeutic
products for patients with diseases such as diabetes and pulmonary
arterial hypertension. MannKind is currently
commercializing Afrezza® (insulin human) Inhalation Powder, the
Company's first FDA-approved product and the only inhaled
rapid-acting mealtime insulin in the United States, where
it is available by prescription from pharmacies
nationwide. MannKind is headquartered in Westlake
Village, California, and has a state-of-the art manufacturing
and research facility in Danbury, Connecticut. The
Company also employs field sales and medical representatives across
the U.S. For further information,
visit www.mannkindcorp.com.
About AMSL AMSL is a private
entity operating exclusively in Australia and has been involved in
the provision of hi-tech medical devices and pharmaceuticals since
the early 1980s. AMSL has been involved in the Australian diabetes
arena for many years where they have introduced many innovations in
the fields of insulin delivery and blood glucose monitoring systems
that have enabled thousands of people living with diabetes to enjoy
a better quality of life and reduce their risk of long-term
complications.
Forward-Looking StatementsThis
press release contains forward-looking statements that involve
risks and uncertainties. Words such as "believes," "anticipates,"
"plans," "expects," "intends," "will," "goal," "potential" and
similar expressions are intended to identify forward-looking
statements. These forward-looking statements are based
upon MannKind's current expectations. Actual results and
the timing of events could differ materially from those anticipated
in such forward-looking statements as a result of various risks and
uncertainties detailed in MannKind's filings with
the SEC. For a discussion of these and other factors, please
refer to MannKind’s quarterly report on Form 10-Q for the quarter
ended March 31, 2019 as well as MannKind’s other filings with
the SEC. You are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
of this press release. All forward-looking statements are qualified
in their entirety by this cautionary statement,
and MannKind undertakes no obligation to revise or update
any forward-looking statements to reflect events or circumstances
after the date of this press release.
MannKind Contact: Rose Alinaya Investor
Relations 818-661-5000 ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Aug 2024 to Sep 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Sep 2023 to Sep 2024